YABAO PHARM.CORP: ZY-A002 has received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.
YABAO PHARM.CORP recently received approval from the National Medical Products Administration for the clinical trial notification of the drug ZY-A002, with the number 2025LP02459. This drug will be used for confirmatory clinical trials of cough variant asthma in children, with indications including dispelling wind and promoting lung function, relieving spasms and stopping cough, primarily targeting symptoms such as coughing fits and throat itching
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments